ADC Therapeutics SA - notizie pubblicate 183 - letture 4.736
ADC THERAPEUTICS SA
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Boston and shanghai, china and lausanne, switzerland, july 24, 2023 (globe newswire) -- overland adct biopharma, a joint venture of overland pharmaceuticals (cy) inc. and adc thera ...
ADC THERAPEUTICS SA
Current Report by Foreign Issuer - Form 6-K
Information contained in this report on form 6-k on july 20, 2023, adc therapeutics sa (the "company") announced that it plans to discontinue the phase 2 lotis-9 clinical ...
ADC THERAPEUTICS SA
ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
Lausanne, switzerland, july 20, 2023 (globe newswire) -- adc therapeutics sa (nyse: adct) today announced that it plans to discontinue the phase 2 lotis-9 clinical trial evaluating ...
ADC THERAPEUTICS SA
Current Report by Foreign Issuer - Form 6-K
United states securities and exchange commission washington, d.c. 20549 form 6-k report of foreign private issuer pursuant to rule 13a-16 or 15d-16 under the securities exchange ac ...
ADC THERAPEUTICS SA
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
Lausanne, switzerland, july 11, 2023 (globe newswire) -- adc therapeutics sa (nyse: adct) today announced a voluntary pause in the enrollment of new patients in the phase 2 lotis-9 ...
ADC THERAPEUTICS SA
Articles of Association of ADC Therapeutics SA - Form 6-K
Articles of association of adc therapeutics sa section 1 name, registered office, purpose and duration of the company section 1 raison sociale, siège, but de la société, durée ...
ADC THERAPEUTICS SA
ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress
Poster presentation will highlight durable, long-term responses in relapsed/refractory dlbcl patients treated with zynlonta® lausanne, switzerland--(business wire)-- adc therapeut ...
ADC THERAPEUTICS SA
ADC Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer adc therapeutics sa ...
ADC THERAPEUTICS SA
ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update
1q 2023 zynlonta®1 net sales increased 15% and operating expenses decreased 19% year-over-year2; fy 2023 guidance reaffirmed for zynlonta double-digit net sales growth and reducti ...
ADC THERAPEUTICS SA
Consolidated Financial Statements - Form 6-K
Exhibit 99.1 unaudited ifrs condensed consolidated interim financial statements as of and for the three months ended march 31, 2023. condensed consolidated interim statement of ope ...
ADC THERAPEUTICS SA
To the shareholders of ADC Therapeutics SA - Form 6-K
To the shareholders of adc therapeutics sa invitation to the annual general meeting date and time: wednesday, june 14, 2023, at 4:00 a.m. edt / 10:00 a.m. cest location: headquarte ...
ADC THERAPEUTICS SA
ADC Therapeutics to Host First Quarter 2023 Financial Results Conference Call on May 9, 2023
Lausanne, switzerland--(business wire)-- adc therapeutics sa (nyse: adct) today announced that it will host a conference call and live webcast on tuesday, may 9, 2023 at 8:30 a.m. ...
ADC THERAPEUTICS SA
Notice of Effectiveness - Form EFFECT
United states securities and exchange commission washington, d.c. 20549 notice of effectiveness effectiveness date: march 24, 2023 4:30 p.m. form: f-3 cik: 0001771910 company name: ...
ADC THERAPEUTICS SA
Notice of Effectiveness - Form EFFECT
United states securities and exchange commission washington, d.c. 20549 notice of effectiveness effectiveness date: march 20, 2023 accession number: 0000950103-22-014035 submission ...
ADC THERAPEUTICS SA
Registration Statement by Foreign Issuer - Specific Transactions - Form F-3
As filed with the securities and exchange commission on march 15, 2023. registration no. 333- united states securities and exchange commission washington, d.c. 20549 form f-3 regis ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti